The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA
Open accessAbstract
P53 is a critical tumor suppressor gene, activating p53 and its downstream targets to induce apoptosis is a promising way for cancer therapy. However, more than 50% of cancer patients have p53 mutations, which may cause cancer therapy resistance, and the underline mechanism is poorly understood. Here, we found that cell viability decrease and apoptosis induced by p53-dependent traditional drugs in colon cancer cells were eliminated in p53 mutant cells. Mutant p53 did not up-regulate the expression of its direct downstream targets PUMA and p21, due to the inhibition of PUMA transcription. Furthermore, mutant p53 could not bind to the promoter of PUMA to activate its transcription like WT p53 did, while overexpressed WT p53 rescued PUMA-induced subsequent apoptosis. In conclusion, our findings demonstrate mutant p53 may cause chemo-resistance of tumor because of inactivating PUMA transcription, which prompts some new insights for clinical therapy of cancer patients with mutant p53.Abbreviations CRC: Colorectal cancer; CDKs: Cyclin-dependent kinases; PUMA: p53 up-regulated modulator of apoptosis; PDGF: the platelet-derived growth factor; WT p53: wild-type p53 protein; mutp53: mutant p53 proteins; BAX: Bcl-2-associated X protein; NOXA: Phorbol-12-myristate-13-acetate-induced protein 1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The cancer-related proteins are abnormally expressed (overexpressed, low expressed, or mutant) in cancer cells compared to normal cells.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [18]
In the citing paper
“TP53 mutations cause poor responses to various therapies 32, 33, including immunotherapy and chemotherapy.”
From Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer (2026) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“CRC is one of the first tumor types to be recognized as a genetic disease, in which the accumulation of genetic alterations leads to highly proliferative and invasive cancers [32].”
BackgroundVogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Global patterns and trends in colorectal cancer incidence and mortality
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310912 · Cited by 5,228
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · cited 1×
“The research revealed LiFraumeni patients with p53 mutations that confer a higher risk of cancer [37,38].”
BackgroundPyroptosis: host cell death and inflammation
Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,183
PUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315
Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead and Dying Eukaryotic Cells
Fink, S. L., & Cookson, B. T. (2005) · Infection and Immunity · doi:10.1128/iai.73.4.1907-1916.2005 · Cited by 2,205
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“Thirdly, previous studies have shown that WT p53 can directly activate BAX by their interaction and changing BAX conformation [54].”
BackgroundTumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Research works printed but not linked: 1
- Audrey P, 2010, Hum Mutat, 28, 622
Cited by
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
“Colon cancer PUMA Causes chemoresistance [109]”
BackgroundThe Role of p53 Signaling in Colorectal Cancer
Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 318
Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches
Alvarado-Ortiz, E., de la Cruz-López, K. G., Becerril-Rico, J., Sarabia-Sánchez, M. A., Ortiz-Sánchez, E., & García-Carrancá, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607670 · Cited by 180
“PUMA is a critical upstream activator of the proapoptotic protein BAX, thus mutp53 decreases BAX activity and hence the apoptotic process (Huang et al., 2019).”
BackgroundDrug toxicity assessment: cell proliferation versus cell death
Sazonova, E. V., Chesnokov, M. S., Zhivotovsky, B., & Kopeina, G. S. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01207-x · Cited by 152
“The colorectal adenocarcinoma SW620 cell line has a R273H mutation in the p53 protein that has a dominant-negative effect on DNA binding and p53-dependent gene expression [19].”
BackgroundThe Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
Michel, M. S., Kaps, L., Maderer, A., Galle, P. R., & Moehler, M. H. (2021) · Cancers · doi:10.3390/cancers13102296 · Cited by 127
“wer able to show t at ch moresistance in mutant p53 cells is b cause of a LOF mu ation to activate downstream PUMA-transcription [63].”
BackgroundInfluential
Metadata
- Authors
- Huang, Y., Liu, N., Liu, J., Liu, Y., Zhang, C., Long, S., Luo, G., Zhang, L., & Zhang, Y.
- Affiliations
- Hunan University (CN)
- Central South University (CN)
- Corresponding author
- Zhang, Lingling
- Zhang, Yingjie
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2019-11-14
- Volume
- 18
- Issue
- 24
- Pages
- 3442-3455
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- PMC
- PMC6927701
- OpenAlex
- W2988051531
- Cited by
- 94
- References
- 66
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 18 · 2023: 16 · 2022: 18 · 2021: 10 · 2020: 6
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cell Cycle (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- the Basic Research Program of Shenzhen Municipal Science and Technology Innovation Committee (JCYJ20160530192802733)
- the National Natural Science Foundation of China (31801140, 31701132 and 31602118)
- Fundamental Research Funds for Central Universities of the Central South University (Nos. 531118040098 and 14700-502044001)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- mutant p53, chemoresistance, PUMA, transcriptional repression, apoptosis, colorectal cancer, p21, p53 tumor suppressor, Bax, Noxa, cyclin-dependent kinases, platelet-derived growth factor
- MeSH terms
- Loss of Function Mutation, Cell Survival, Colonic Neoplasms, Humans, Proto-Oncogene Proteins, Transcription, Genetic, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, HCT116 Cells, Mutant Proteins, Apoptosis Regulatory Proteins, bcl-2-Associated X Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA. https://app.cochat.ai/papers/10.1080/15384101.2019.1688951
- The paper
- Huang, Y., Liu, N., Liu, J., Liu, Y., Zhang, C., Long, S., Luo, G., Zhang, L., & Zhang, Y. (2019). Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA. Cell Cycle. https://doi.org/10.1080/15384101.2019.1688951
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.